fda amgen - Search News

Amgen, Obesity and FDA

Amgen Discloses FDA Paused Study of Early-Stage Obesity Drug

Amgen Inc. sees the potential for 2025 revenues to top Wall Street estimates thanks to growth in cholesterol and cancer drugs.

Hosted on MSN · 13h

Amgen Shrugs Off A Surprise Setback For One Of Its Obesity Drugs

Amgen stock rose early Wednesday, though the biotech behemoth said the FDA placed one of its obesity treatments on clinical hold.

STAT · 1d

Study of Amgen’s early obesity candidate paused by FDA

The company said the agency's hold was "not related to the drug,” dubbed AMG 513, and that discussions were underway to reopen the study.

FiercePharma13h

With recent launches and more to come, Amgen's biosimilar business is trending up

After recent launches of biosimilar versions of Eylea and Stelara, Amgen projects its biosimilar sales will reach $4 billion ...

Amgen profits rise, next MariTide studies start by mid-year

Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug ...

BioSpace16h

Pipeline Problems Mar Amgen’s Q4 Beat

Amgen outperformed expectations in the fourth quarter of 2024, but revealed an FDA hold on early-stage obesity asset AMG 513 ...

10h

Amgen Q4 Earnings: Strong Pipeline And Label Expansions Justify Buy Rating

Amgen's Q4 earnings beat expectations, showcasing robust performance for the company's growth strategy. Click here to read ...

12h

Amgen Impresses With Q4 Earnings Beat, Analysts See Growth Ahead

Amgen posted Q4 sales of $9.1 billion, up 11%, surpassing forecasts. EPS beat estimates, and analysts remain optimistic about growth prospects in 2025.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results